Skip to main navigation

Investor Relations

Home
Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Coverage

Year

Apr 07, 2022

FDA Approves Novel Therapy for Schizophrenia and Bipolar

Apr 07, 2022

FDA approves Igalmi for agitation associated with schizophrenia or bipolar I or II disorder

Apr 06, 2022

FDA clears BioXcel's schizophrenia, bipolar treatment Igalmi

Apr 06, 2022

Igalmi Sublingual Film Approved for Agitation With Schizophrenia, Bipolar Disorder

Apr 06, 2022

FDA Approves Dissolving Sublingual Film for Agitation in Schizophrenia, Bipolar I or II

Apr 06, 2022

FDA approves BioXcel Therapeutics drug for agitation

Apr 06, 2022

Psych and neuro R&D notch a win as BioXcel gets FDA approval for schizophrenia, bipolar disorder-related agitation

Apr 06, 2022

A Win for AI: FDA Approves BioXCel Therapy for Bipolar Disorder & Schizophrenia

Feb 28, 2022

Sublingual Dexmedetomidine May Rapidly Calm Bipolar Agitation

Feb 23, 2022

Sublingual Dexmedetomidine Beneficial Against Severe Agitation in Bipolar Disorders: JAMA

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Displaying 11 - 20 of 24

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Home
Investors & Media
Contact Us
Careers

Copyright © 2022 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap